SCHEMBL2837826

SCHEMBL2837826

O=S(=O)(Nc1cc(CO)nn1-c1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
CYP2C9 P11712 6/20 0.55
POLB P06746 2/20 0.53
GLA P06280 1/20 0.51
CA1 P00915 4/20 0.50
CA2 P00918 4/20 0.50
CA9 Q16790 4/20 0.50
PTGS2 P35354 1/20 0.49
CACNA1G O43497 1/20 0.46
CACNA1H O95180 1/20 0.46
KCNH2 Q12809 1/20 0.46
LMNA P02545 3/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
CYP2C18 P33260 1/20 0.46
THPO P40225 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25351301 0.78 ALDH1A1 (0.60) ALDH1A1CYP2C9POLBGLALMNA
SCHEMBL16780330 0.77 ALDH1A1 (0.59) ALDH1A1POLBLMNATSHRNPSR1
SCHEMBL8694140 0.77 ALDH1A1 (0.59) ALDH1A1CYP2C9POLBGLAPTGS2
SCHEMBL2834738 0.77 ALDH1A1 (0.59) ALDH1A1CYP2C9POLBGLALMNA
SCHEMBL8691662 0.76 ALDH1A1 (0.57) ALDH1A1CYP2C9POLBGLAPTGS2
SCHEMBL8953991 0.76 ALDH1A1 (0.57) ALDH1A1CYP2C9POLBGLALMNA
SCHEMBL2839406 0.76 GAA (0.60) ALDH1A1CA1CA2CA9PTGS2
SCHEMBL28210277 0.75 ALDH1A1 (0.50) ALDH1A1POLBCA1CA2CA9
SCHEMBL2835329 0.74 ALDH1A1 (0.56) ALDH1A1CYP2C9POLBCA9LMNA
SCHEMBL2837900 0.74 GAA (0.67) ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP disclosed
EP-2196459-B1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-11-02 EP disclosed
US-8334301-B2 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-18 US disclosed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND NPY4R, NPY5R, NPY1R ALDH1A1 2505/4885CYP2C9 508/4885POLB 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.